The District of Delaware must revisit whether a patent for Forest Laboratories LLC’s schizophrenia drug Saphris is valid, the Federal Circuit ruled March 14.
The U.S. District Court for the District of Delaware will also have to reweigh whether Breckenridge Pharmaceutical Inc. and Alembic Pharmaceuticals Ltd. infringed the Saphris patent.
Sigmapharm Laboratories LLC filed an Abbreviated New Drug Application to market a generic version of Forest’s Saphris, an antipsychotic drug administered under the tongue or inside the cheek. Saphris is...
For more stories, analysis and expertiseOR Request Trial
(Updated with additional reporting throughout)